

Division of Medical Services Medicaid Pharmacy Program P.O. Box 1437, Slot S415, Little Rock, AR 72203-1437 P: 501.683.4120 F: 800-424-5851

November 1, 2024

RE: Preferred Drug List (PDL) updates Trileptal® (oxcarbazepine) suspension

Prescribers and pharmacists,

Prior to December 2023, brand name Trileptal[®] suspension was the preferred option as a state supported brand. Starting in December 2023, there was availability issues for the brand name. In an effort to ensure patients were able to continue this anticonvulsant, Arkansas Medicaid temporarily moved the generic (oxcarbazepine suspension) into a preferred status along with the brand Trileptal[®]. Shortages for the brand name seem to have been resolved. Therefore, the generic oxcarbazepine suspension will move back to a non-preferred status effective <u>December 1, 2024</u>. Prescriptions should be dispensed with brand Trileptal[®] suspension at that time using DAW code 9 for proper reimbursement.

For any questions, contact the Prime Therapeutics Help Desk at 800-424-7895.

Sincerely,

Cynthia Neuhofel, Pharm.D. DMS Assistant Director/Pharmacy Director